Ophthalmology
Partner With Us
Advertisement
Commentary & Perspectives

Novel glucose-lowering medications and impact on diabetic retinopathy

Andrew J. Barkmeier, M.D. presents an update on new glucose-lowering medications and their impact on diabetic retinopathy.

Mayo Clinic
Andrew J. Barkmeier, M.D. discusses recent advances in glucose-lowering medications, including the systemic health benefits of GLP-1 RA medications in type 2 diabetes, potential risk factors for accelerated diabetic retinopathy progression and different categories of novel glucose-lowering medications for type 2 diabetes.